This event will cover key considerations for optimizing pulmonary drug delivery and improving speed-to-clinic for dry powder inhalant (DPI) applications. A combination of formulation expertise, material science, particle engineering and equipment platform leads to an API independent platform capable of aerosol independent dose ranging and rapid progression to clinical supplies. In addition, important aspects of the capsule interaction with the DPI device will be presented including the wide range of customization services to closely match Customers specific requirements.
Capsugel scientists will discuss the:
A representative case study using a model compound will be presented that demonstrates this pulmonary platform approach.
Please note that Lonza has updated its Privacy Policy. By visiting our website or using services provided by Lonza, you are accepting the practices described in the Privacy Policy.
We also use cookies on our websites. Cookies allow us to give you the best browsing experience and help us to understand how you use our site. You can disable cookies but parts of our website may not work. Please read our updated Cookies Policy for information about which cookies we use and the information we collect. By continuing to use this website, you agree that we may store and access cookies on your device.
By clicking "I Agree", you confirm that you are above the age of 16, that you have read and understood the Privacy Policy and the Cookies Policy, and that you agree to the collection, use and processing of your Personal Information by Lonza in accordance with said policies.